You are about to leave doptelethcp.com and go to an external page.
Please note that Sobi is not responsible for the content of the website you are about to visit.
CONTINUEGo back
For US healthcare professionals only
- Important Safety Information
- Prescribing Information
- Patient Information Leaflet
- For Patients
For US healthcare professionals only
More Platelets
For adults with thrombocytopenia in chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Less Compromise
Doptelet is the only oral TPO-RA with no food-type restrictions, no liver monitoring, and no injections.1-3*†
Food required.
Platelet monitoring required. After initiating therapy with Doptelet, assess platelet counts weekly until a stable platelet count of ≥50x109/L has been achieved, and then obtain platelet counts monthly thereafter.
Rapid and durable response in the 6-month core study:
In the pivotal trial and open-label extension:
50K
Raise and maintain
With Doptelet, keep platelet counts lifted at 50,000/μL.1‡
12.4W
Keep platelet counts lifted
Patients on Doptelet reached target platelet counts of 50,000 platelets/μL for a median of 12.4 cumulative weeks.1
8Days
Lift platelet counts quickly
Most patients reached 50,000 platelets/μL in as few as 8 days with Doptelet.1§
In the pivotal trial and open-label extension:
94%
Reach target levels
94% of patients reached 50,000 platelets/μL at least once in Doptelet clinical trials.3||
Core Study: Efficacy was evaluated in a 6-month, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. Patients had previously received one or more prior chronic ITP therapies and had average screening and baseline platelet counts of <30×109/L. Forty-nine patients were randomized (2:1) to receive either Doptelet (n=32) or placebo (n=17).
- The primary efficacy endpoint was the cumulative number of weeks of platelet response, defined as a platelet count ≥50×109/L in the absence of rescue therapy, over 6 months of once-daily treatment in adults with chronic ITP. Doptelet-treated patients had a median duration of 12.4 cumulative weeks vs 0 weeks for placebo
- A secondary efficacy endpoint was the proportion of patients with a platelet response (platelet counts ≥50×109/L) at Day 8. 66% (n=21/32) of Doptelet-treated patients had platelet counts of ≥50,000/μL at Day 8 compared to placebo (n=0/17)
Open-label extension: Patients could enter the open-label extension phase if they completed the 6-month core study, or if they experienced a lack of efficacy during that period. In the extension phase, all patients received titrated Doptelet once daily. Thirty-nine patients (24 Doptelet and 15 placebo) entered the 90-week maintenance period of the extension phase, in which Doptelet dose titration and downward titration of concomitant ITP medications were allowed. At the end of the extension phase, a 4-week, dose-tapering period was followed by a 30-day follow-up after the last dose of Doptelet.2,4
- The primary endpoint of the extension study was to assess the long-term safety and efficacy of treatment with Doptelet by measuring platelet response rate, bleeding, and the use of rescue therapy2
- Exploratory endpoints included the percentage of patients who achieved platelet counts ≥50,000/μL or ≥100,000/μL at any time during the core study and its extension phase. These endpoints were reported in an integrated analysis of the Phase 3 core study and extension phase data. In an integrated analysis of the core study and its extension phase, 93.8% of patients initially randomized to Doptelet and who continued to be treated with Doptelet during the extension phase achieved a platelet count of ≥50,000/μL at any time, compared to 64.7% of placebo patients who rolled over to Doptelet.4,6
Important Safety Information
WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.
No food-type restrictions
Patients can take Doptelet with any food (food required); no administration concerns with minerals like calcium or magnesium.1
No liver monitoring
Doptelet does not require additional liver-function monitoring; no significant hepatotoxicity seen in Doptelet clinical trials.1,2
No injections
Doptelet can be taken anytime, anywhere, without adding trips to the doctor (platelet monitoring required).1†
Remember to monitor for drug interactions and platelet response.†
Food required.1
Platelet monitoring required. After initiating therapy with Doptelet, assess platelet counts weekly until a stable platelet count of ≥50x109/L has been achieved, and then obtain platelet counts monthly thereafter.1
Throughout the core study and extension phase, 72.3% of patients were exposed to avatrombopag for at least 32 weeks. In the open-label extension phase for those patients continuing Doptelet treatment, a response was achieved at 44.2% of visits.2,4
Study Design: Efficacy was evaluated in a 6-month, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. Patients had previously received one or more prior chronic ITP therapies and had average screening and baseline platelet counts of <30×109/L. Forty-nine patients were randomized (2:1) to receive either Doptelet (n=32) or placebo (n=17).1
- The primary efficacy endpoint was the cumulative number of weeks of platelet response, defined as a platelet count ≥50×109/L in the absence of rescue therapy, over 6 months of once-daily treatment in adults with chronic ITP
- A secondary efficacy endpoint was the proportion of patients with a platelet response (platelet counts ≥50×109/L) at Day 81
Exploratory endpoints were reported in an integrated analysis of the Phase 3 Core Study and Extension Phase data. Patients could enter the Extension Phase if they completed the 6-month Core Study, or if they experienced a lack of efficacy during that period. In the Extension Phase, all patients received open-label titrated Doptelet. Thirty-nine patients entered the Extension Phase (24 Doptelet and 15 placebo).3,4
Dop•Tell•It Like It Is
Doptelet Patient Experience
Mechanism of action
Doptelet works with the body to increase platelet production.1
Find out more about the recommended use of TPO-RAs
- The American Society of Hematology (ASH) guidelines recommend the use of TPO-RAs as a second-line therapy6¶
- The updated International Primary ITP Consensus Report recommends the use of TPO-RAs as a therapy subsequent to initial therapy7
TPO-RA=thrombopoietin receptor agonist.
Avatrombopag was not studied as part of the 2019 ASH guidelines.
Any questions?
Our support specialists can help answer your questions about Doptelet and access options —
call 833-368-2663.
Monday–Friday 8 AM–8 PM ET.
Read about Doptelet efficacy
Doptelet worked to raise platelet counts in patients with ITP in the Phase 3 clinical study. Ready to see the numbers?1†
View Efficacy
References:
- 1. DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
- 2. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490.
- 3. Nagalla S, Vredenburg M, Tian W, Allen LF. Platelet response to avatrombopag in patients with chronic immune thrombocytopenia: additional analyses from a phase 3 study and its extension. Blood. 2019;134(suppl 1):1071.
- 4. Al-Samkari H, Aggarwal K, Vredenburg M, Tian W, Allen LF. Long-term response rates in patients with chronic immune thrombocytopenia treated with avatrombopag: additional analyses from a phase 3 study and its extension phase. Blood. 2019;134(suppl 1):2356.
- 5. Nplate [prescribing information]. Thousand Oaks, CA: Amgen.
- 6. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
- 7. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.
Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.
DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.
Serious Adverse Reactions
Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).
Adverse Reactions
The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.
Postmarketing Experience
Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.
These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.
For WAC pricing, visit doptelethcp.com/wac-pricing.
INDICATION
DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
